Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations (2020 - 2025)

Historic Income from Continuing Operations for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to -$52.9 million.

  • Rhythm Pharmaceuticals' Income from Continuing Operations fell 2122.55% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 2572.22%. This contributed to the annual value of -$260.6 million for FY2024, which is 4111.16% down from last year.
  • Rhythm Pharmaceuticals' Income from Continuing Operations amounted to -$52.9 million in Q3 2025, which was down 2122.55% from -$46.6 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Income from Continuing Operations high stood at $43.8 million for Q1 2021, and its period low was -$141.4 million during Q1 2024.
  • In the last 5 years, Rhythm Pharmaceuticals' Income from Continuing Operations had a median value of -$44.2 million in 2023 and averaged -$44.9 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first soared by 22805.88% in 2021, then plummeted by 22007.09% in 2022.
  • Rhythm Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$50.9 million in 2021, then grew by 16.44% to -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then dropped by 3.98% to -$43.3 million in 2024, then fell by 22.2% to -$52.9 million in 2025.
  • Its last three reported values are -$52.9 million in Q3 2025, -$46.6 million for Q2 2025, and -$49.5 million during Q1 2025.